Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine

Antiviral Therapy

Volumn 2, Issue 1, 1997, Pages 31-38

  Foli, Andrea ^a  

^a Res Inst Genetic and Hum Ther   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; ZIDOVUDINE;

EID: 0030952061     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiological Review 1995; 8:200-239.
2. D'Aquila R. HIV-1 chemotherapy and drug resistance. Clinical Diagnostic Virology 1995; 3:299-316.
3. Kimberlin DW, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M. Richman DD & Whitley RJ. Antiviral resistance in clinical practice. Antiviral Research 1995; 20:423-438.
4. Gao WY, Cara A, Gallo RC & Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 1993; 90:8925-8928.
5. Young CW, Schochetman G, Hodas S & Balls ME. Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. Cancer Research 1967; 27:535-540.